Document is current
Any future updates will be listed below
-
Authors
Naamneh-Abuelhija, Badera
Kafri, Michal https://orcid.org/0000-0002-9405-5699
Kestenbaum, Meir
Giveon, Shmuel
Kamah, Sharon
Shved, Sarit
Yogev-Seligmann, Galit https://orcid.org/0000-0002-4555-6665
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05209698 at ClinicalTrials.govDocuments that mention this clinical trial
Concealment of Parkinsons disease prevalence and impact on health and quality of life
https://doi.org/10.1038/s41598-025-91579-8
-
Funding
Funding for this research was provided by:
Israel Science Foundation (756/22)
- License Information
-
More Information
Article History
Received: 8 October 2024
Accepted: 21 February 2025
First Online: 4 March 2025
Declarations
:
: Study procedures were performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Faculty of Social Welfare & Health Sciences, University of Haifa (approval number 548/20) and the Helsinki Committee of Clalit Health Services (approval number 0128-19-COM1). All participants signed a consent form prior to entering the study.
: The authors declare no competing interests.
